Clinical trials: Oligometastasis
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Advanced Hepatocellular Carcinoma, Lung Cancer
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical…
- Conditions
- Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
- Trial name
- NCT06644430
- Testing
- Ablation, system therapy
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis
The purpose of this study is to evaluate feasibility to treat metachronous multi-site breast cancer oligometastasis with stereotactic body radiotherapy (SBRT) in patients on systemic therapy.
- Trial name
- STOMP (NCT03295916)
- Testing
- Stereotactic Body Radiotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Juravinski Cancer Center
Pancreatic Cancer Non-resectable
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer.
- Trial name
- NCT07386704
- Testing
- Nimotuzumab combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
The overall aim of this project is to test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic disease prolongs the metastases progression-free…
- Trial name
- ADOPT (NCT04302454)
- Testing
- Radiotherapy, Leuprorelin
- Where
- 13 sites in Netherlands
- Volunteers
- 280 people
- Sponsor
- University Medical Center Groningen
Lung Adenocarcinoma
Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene
This prospective phase II study is determined to explore the efficacy and safety of radiotherapy and bevacizumab maintenance therapy for oligometastatic lung adenocarcinoma with negative driver genes
- Trial name
- NCT03905317
- Testing
- Bevacizumab Injection, chest radiation, concurrent chemotherapy
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Brain Metastases, Adult
Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis
This trial aims to assess the impact of SRS on overall survival, PFS, radiation toxicity and quality of life as compared to WBRT in oligometastatic brain disease in breast cancer patients.
- Conditions
- Breast Cancer, Brain Metastases, Adult, Stereotactic Radiosurgery, Whole Brain Radiotherapy
- Trial name
- SRSvsWBRT (NCT05144867)
- Testing
- Stereotactic Radiosurgery
- Where
- India
- Volunteers
- 98 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Metastatic Colorectal Cancer
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
Metastatic colorectal cancer is one of the common malignant tumors and the overall prognosis is poor. The introduction of immune-checkpoint inhibition (ICI) has led to a paradigm shift in the treatment of patients with metastatic…
- Trial name
- NCT03927898
- Testing
- Toripalimab, Stereotactic Body Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Oligometastatic Disease
Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care
Currently, the usual standard of palliative treatment used in patients with diagnosed oligometastatic cancer in accordance with the local clinical recommendations is chemotherapy and/or a symptomatic course of radiation therapy…
- Trial name
- NCT06556550
- Testing
- stereotactic ablative radiation therapy, palliative radiation therapy, Chemotherapy
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Brain Oligometastatic, Non-small Cell Lung Cancer
Brain Oligometastasis in NSCLC
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized.
- Trial name
- OligoLung (NCT07389642)
- Testing
- Standard treatments / multiple strategies
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Bordeaux
NSCLC Stage IV, Oligometastasis
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC, from back-line to first-line, and…
- Trial name
- NCT05055583
- Testing
- Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Prostate Cancer, Prostate Cancer Recurrent
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed…
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- SPARKLE (NCT05352178)
- Testing
- Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
- Where
- Belgium
- Volunteers
- 873 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Nasopharyngeal Carcinoma, Oligometastasis
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease.
- Conditions
- Nasopharyngeal Carcinoma, Oligometastasis, Radiotherapy
- Trial name
- NCT04221516
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Oligometastatic Prostate Cancer
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen DeprIvation therapy in metachronous prostate cancer OligometaStAsis).
- Trial name
- RADIOSA (NCT03940235)
- Testing
- Androgen deprivation therapy (ADT), SBRT
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Advanced Hepatocellular Carcinoma, Oligometastasis
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
- Conditions
- Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
- Trial name
- NCT06550921
- Testing
- ablation of oligometastasis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Cancer, Cervical, Recurrence
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study
This multi centric international retrospective study aims to register patients with oligo metastatic and oligo recurrent cervical cancer.
- Conditions
- Cancer, Cervical, Recurrence, Metastasis
- Trial name
- Retro-COSMOS (NCT06150222)
- Testing
- Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)
- Volunteers
- 350 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer Metastatic
Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone
This study is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer.
- Trial name
- NCT03988686
- Testing
- Radical prostatectomy plus standard care, Standard of care for metastatic prostate cancer
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Prostate Cancer - Recurrent
HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer
The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short…
- Trial name
- BEACON (NCT03553602)
- Testing
- HDR Brachytherapy + EBRT + STAD
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loyola University
Head and Neck Squamous Cell Carcinoma
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
The aim of this study is to evaluate the rate of living patients at 1 year with a quality of life criteria (no decrease) and reduced toxicities.
- Trial name
- OMET (NCT03070366)
- Testing
- Chemotherapy, Stereotactic radiotherapy
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Rectal Cancer, Head and Neck Cancer
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.
- Conditions
- Rectal Cancer, Head and Neck Cancer, Liver Cancer, Breast Cancer
- Trial name
- NCT04172753
- Testing
- Radiotherapy on the MR-Linac, Imaging on the MR Linac
- Where
- Germany
- Volunteers
- 472 people
- Sponsor
- University Hospital Tuebingen